Abstract
LASSBio-542 is a thalidomide analog synthesized as a 2-phenoxy-phthalimide derivative with the ability to inhibit Tumor Necrosis Factor-alpha (TNFα), behaving similarly in some instances to the original drug in vitro and in animal models. In new experiments comparing the biological activities of both drugs, we identified LASSBio-542 as an immunomodulator compound with extra properties dissimilar to those of thalidomide. While the extent of TNFα, IL-12p40 and IL-1β production stimulated by Lipopolysaccharide (LPS) inhibition was similar to thalidomide, Interleukin(IL)-10 production was inhibited by LASSBio-542; and Nuclear Factor kappa-B (NFκB) activation via proinflammatory stimulus was also inhibited by both drugs. In the same vein, angiogenesis was impaired while endothelial cell migration was affected by LASSBio-542 alone. Modulation of pro-angiogenic factors induced by TNFα in Human Umbilical Endothelial Vein Cells (HUVEC) such as IL-8, Vascular Endothelial Growth Factor-A (VEGF-A), Cyclooxygenase-2(COX-2), and TNFα itself was also observed by semiquantitative real-time PCR. The study of this molecule may provide new insights into thalidomide mechanisms and new therapeutic options for diseases characterized by singular alterations in the cytokine networks and angiogenesis impairments.
Keywords: Thalidomide, TNFα, IL-10, VEGF, angiogenesis, NFκB, immunomodulator, LASSBio-542, angiogenesis, COX.
Current Bioactive Compounds
Title:LASSBio-542: Novel Thalidomide Analog Distinctly Modulates IL-10 and Inhibits Angiogenesis
Volume: 8 Issue: 2
Author(s): Daniel Serra de Carvalho, Lidia Moreira Lima, Eliezer Jesus de Lacerda Barreiro, Tercia R. Alves, Jose Augusto da Costa Nery, Euzenir N. Sarno and Elizabeth P. Sampaio
Affiliation:
Keywords: Thalidomide, TNFα, IL-10, VEGF, angiogenesis, NFκB, immunomodulator, LASSBio-542, angiogenesis, COX.
Abstract: LASSBio-542 is a thalidomide analog synthesized as a 2-phenoxy-phthalimide derivative with the ability to inhibit Tumor Necrosis Factor-alpha (TNFα), behaving similarly in some instances to the original drug in vitro and in animal models. In new experiments comparing the biological activities of both drugs, we identified LASSBio-542 as an immunomodulator compound with extra properties dissimilar to those of thalidomide. While the extent of TNFα, IL-12p40 and IL-1β production stimulated by Lipopolysaccharide (LPS) inhibition was similar to thalidomide, Interleukin(IL)-10 production was inhibited by LASSBio-542; and Nuclear Factor kappa-B (NFκB) activation via proinflammatory stimulus was also inhibited by both drugs. In the same vein, angiogenesis was impaired while endothelial cell migration was affected by LASSBio-542 alone. Modulation of pro-angiogenic factors induced by TNFα in Human Umbilical Endothelial Vein Cells (HUVEC) such as IL-8, Vascular Endothelial Growth Factor-A (VEGF-A), Cyclooxygenase-2(COX-2), and TNFα itself was also observed by semiquantitative real-time PCR. The study of this molecule may provide new insights into thalidomide mechanisms and new therapeutic options for diseases characterized by singular alterations in the cytokine networks and angiogenesis impairments.
Export Options
About this article
Cite this article as:
Serra de Carvalho Daniel, Moreira Lima Lidia, Jesus de Lacerda Barreiro Eliezer, R. Alves Tercia, Augusto da Costa Nery Jose, N. Sarno Euzenir and P. Sampaio Elizabeth, LASSBio-542: Novel Thalidomide Analog Distinctly Modulates IL-10 and Inhibits Angiogenesis, Current Bioactive Compounds 2012; 8 (2) . https://dx.doi.org/10.2174/157340712801784778
DOI https://dx.doi.org/10.2174/157340712801784778 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Killer Cells Preferentially Target Cancer Stem Cells; Role of Monocytes in Protection Against NK Cell Mediated Lysis of Cancer Stem Cells
Current Drug Delivery Antineoplastic Activity of Monocrotaline Against Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Editorial: [Cytokines as Anti-Cancer Agents Rational, Results and Perspectives (Guest Editor: S. Mocellin)]
Current Medicinal Chemistry Breast Cancer in the Personal Genomics Era
Current Genomics Pharmacokinetics of Gefitinib: Roles of Drug Metabolizing Enzymes and Transporters
Current Drug Delivery Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Sphingolipids Cyclic Derivatives: Occurrence, Biological Relevance and Synthetic Approaches
Current Organic Chemistry Estrogens and Progression of Diabetic Kidney Damage
Current Diabetes Reviews Mitochondrial Post-translational Modifications and Metabolic Control: Sirtuins and Beyond
Current Diabetes Reviews Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry RETRACTED: Aberrant Sialylation in Cancer Pathology and Metastasis, a Putative Drug Target Candidate
Anti-Cancer Agents in Medicinal Chemistry New Insights into Neoangiogenesis and Breast Cancer Development and Progression
Current Angiogenesis (Discontinued) Insights into Nano-Photo-Thermal Therapy of Cancer: The Kinetics of Cell Death and Effect on Cell Cycle
Anti-Cancer Agents in Medicinal Chemistry Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Current Gene Therapy The Re-Emergence of Aerosol Gene Delivery: A Viable Approach to Lung Cancer Therapy
Current Cancer Drug Targets ABC Transporters, Bile Acids, and Inflammatory Stress in Liver Cancer
Current Pharmaceutical Biotechnology Pitfalls and Solutions for the Validation of Novel Drugs in Animal Models of Disease
Current Immunology Reviews (Discontinued)